Your browser doesn't support javascript.
loading
The effect of a proof-of-vaccination requirement, incentive payments, and employer-based mandates on COVID-19 vaccination rates in New York City: a synthetic-control analysis.
Cohn, Ezra; Chimowitz, Michael; Long, Theodore; Varma, Jay K; Chokshi, Dave A.
Afiliación
  • Cohn E; New York City Mayor's Office of Management and Budget, New York, NY, USA. Electronic address: cohne@omb.nyc.gov.
  • Chimowitz M; New York City Mayor's Office of Management and Budget, New York, NY, USA.
  • Long T; New York City Health and Hospitals, New York, NY, USA.
  • Varma JK; Weill Cornell Medicine, New York, NY, USA.
  • Chokshi DA; New York University, Grossman School of Medicine, New York, NY, USA.
Lancet Public Health ; 7(9): e754-e762, 2022 09.
Article en En | MEDLINE | ID: mdl-36057274
ABSTRACT

BACKGROUND:

COVID-19 vaccines have been available to all adults in the USA since April, 2021, but many adults remain unvaccinated. We aimed to assess the joint effect of a proof-of-vaccination requirement, incentive payments, and employer-based mandates on rates of adult vaccination in New York City (NYC).

METHODS:

We constructed a synthetic control group for NYC composed of other counties in the core of large, metropolitan areas in the USA. The vaccination outcomes for NYC were compared against those of the synthetic control group from July 26, 2021, to Nov 1, 2021, to determine the differential effects of the policies. Analyses were conducted on county-level vaccination data reported by the Centers for Disease Control and Prevention. The synthetic control group was constructed by matching on county-level preintervention vaccination outcomes, partisanship, economic attributes, demographics, and metropolitan area population. Statistical inference was conducted using placebo tests for non-treated counties.

FINDINGS:

The synthetic control group resembled NYC across attributes used in the matching process. The cumulative adult vaccination rate for NYC (in adults aged 18 years or older who received at least one dose of an authorised COVID-19 vaccine) increased from 72·5% to 89·4% (+16·9 percentage points [pp]) during the intervention period, compared with an increase from 72·5% to 83·2% (+10·7 pp) for the synthetic control group, a difference of 6·2 pp (95% CI 1·4-10·7), or 410 201 people (90 966-706 532). Daily vaccinations for NYC were consistently higher than those in the synthetic control group, a pattern that started shortly after the start of the intervention period.

INTERPRETATION:

The combination of a proof-of-vaccination requirement, incentive payments, and vaccine mandates increased vaccination rates among adults in NYC compared with jurisdictions that did not use the same measures. Whether the impact of these measures occurred by inducing more people to get vaccinated, or by accelerating vaccinations that would have occurred later, the increase in vaccination rates likely averted illness and death.

FUNDING:

None.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 / 4_TD / 6_ODS3_enfermedades_notrasmisibles Problema de salud: 1_doencas_nao_transmissiveis / 2_enfermedades_transmissibles / 2_muertes_prematuras_enfermedades_notrasmisibles / 4_covid_19 / 4_pneumonia / 6_other_respiratory_diseases Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Clinical_trials Límite: Adult / Humans País/Región como asunto: America do norte Idioma: En Revista: Lancet Public Health Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 / 2_ODS3 / 4_TD / 6_ODS3_enfermedades_notrasmisibles Problema de salud: 1_doencas_nao_transmissiveis / 2_enfermedades_transmissibles / 2_muertes_prematuras_enfermedades_notrasmisibles / 4_covid_19 / 4_pneumonia / 6_other_respiratory_diseases Asunto principal: Vacunas contra la COVID-19 / COVID-19 Tipo de estudio: Clinical_trials Límite: Adult / Humans País/Región como asunto: America do norte Idioma: En Revista: Lancet Public Health Año: 2022 Tipo del documento: Article
...